SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med 2007; 357: 2601-2614.
  • 2
    Winston DJ, Emmanouilides C, Busuttil RW. Infections in liver transplant recipients. Clin Infect Dis 1995; 21: 1077-1089.
  • 3
    Torbenson M, Wang J, Nichols L, Jain A, Fung J, Nalesnik MA. Causes of death in autopsied liver transplantation patients. Mod Pathol 1998; 11: 37-46.
  • 4
    Wiesner RH, Ludwig J, van Hoek B, Krom RA. Current concepts in cell-mediated hepatic allograft rejection leading to ductopenia and liver failure. Hepatology 1991; 14( pt 1): 721-729.
  • 5
    Wiesner RH, Demetris AJ, Belle SH, Seaberg EC, Lake JR, Zetterman RK, et al. Acute hepatic allograft rejection: incidence, risk factors, and impact on outcome. Hepatology 1998; 28: 638-645.
  • 6
    Venkataramanan R, Shaw LM, Sarkozi L, Mullins R, Pirsch J, MacFarlane G, et al. Clinical utility of monitoring tacrolimus blood concentrations in liver transplant patients. J Clin Pharmacol 2001; 41: 542-551.
  • 7
    Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009; 9( suppl 3): S1-S155.
  • 8
    Wieland E, Olbricht CJ, Süsal C, Gurragchaa P, Böhler T, Israeli M, et al. Biomarkers as a tool for management of immunosuppression in transplant patients. Ther Drug Monit 2010; 32: 560-572.
  • 9
    Rodrigo E, Arias M. A practical approach to immune monitoring in kidney transplantation. Minerva Urol Nefrol 2007; 59: 337-352.
  • 10
    Bouwman LH, Roep BO, Roos A. Mannose-binding lectin: clinical implications for infection, transplantation, and autoimmunity. Hum Immunol 2006; 67: 247-256.
  • 11
    Budde K, Matz M, Dürr M, Glander P. Biomarkers of over-immunosuppression. Clin Pharmacol Ther 2011; 90: 316-322.
  • 12
    Mawhorter S, Yamani MH. Hypogammaglobulinemia and infection risk in solid organ transplant recipients. Curr Opin Organ Transplant 2008; 13: 581-585.
  • 13
    Sommerer C, Zeier M, Meuer S, Giese T. Individualized monitoring of nuclear factor of activated T cells-regulated gene expression in FK506-treated kidney transplant recipients. Transplantation 2010; 89: 1417-1423.
  • 14
    Sommerer C, Schnitzler P, Meuer S, Zeier M, Giese T. Pharmacodynamic monitoring of cyclosporin A reveals risk of opportunistic infections and malignancies in renal transplant recipients 65 years and older. Ther Drug Monit 2011; 33: 694-698.
  • 15
    Kowalski RJ, Post DR, Mannon RB, Sebastian A, Wright HI, Sigle G, et al. Assessing relative risks of infection and rejection: a meta-analysis using an immune function assay. Transplantation 2006; 82: 663-668.
  • 16
    Cabrera R, Ararat M, Soldevila-Pico C, Dixon L, Pan JJ, Firpi R, et al. Using an immune functional assay to differentiate acute cellular rejection from recurrent hepatitis C in liver transplant patients. Liver Transpl 2009; 15: 216-222.
  • 17
    Xue F, Zhang J, Han L, Li Q, Xu N, Zhou T, et al. Immune cell functional assay in monitoring of adult liver transplantation recipients with infection. Transplantation 2010; 89: 620-626.
  • 18
    Hashimoto K, Miller C, Hirose K, Diago T, Aucejo F, Quintini C, et al. Measurement of CD4+ T-cell function in predicting allograft rejection and recurrent hepatitis C after liver transplantation. Clin Transplant 2010; 24: 701-708.
  • 19
    Mizuno S, Hamada T, Nakatani K, Kishiwada M, Usui M, Sakurai H, et al. Monitoring peripheral blood CD4+ adenosine triphosphate activity after living donor liver transplantation: impact of combination assays of immune function and CYP3A5 genotype. J Hepatobiliary Pancreat Sci 2011; 18: 226-232.
  • 20
    Dong JY, Yin H, Li RD, Ding GS, Fu ZR, Wu YM, Wang ZX. The relationship between adenosine triphosphate within CD4(+) T lymphocytes and acute rejection after liver transplantation. Clin Transplant 2011; 25: E292-E296.
  • 21
    Cheng JW, Shi YH, Fan J, Huang XW, Qiu SJ, Xiao YS, et al. An immune function assay predicts post-transplant recurrence in patients with hepatocellular carcinoma. J Cancer Res Clin Oncol 2011; 137: 1445-1453.
  • 22
    Hwang S, Kim KH, Song GW, Yu YD, Park GC, Kim KW, et al. Peritransplant monitoring of immune cell function in adult living donor liver transplantation. Transplant Proc 2010; 42: 2567-2571.
  • 23
    Zhou T, Xue F, Han LZ, Xi ZF, Li QG, Xu N, et al. Invasive fungal infection after liver transplantation: risk factors and significance of immune cell function monitoring. J Dig Dis 2011; 12: 467-475.
  • 24
    Jennemann J, Phelan D, Hill R, Willey P, Morris G. Evaluating the efficacy of the ImmuKnow assay in post-transplant monitoring of liver patients [abstract]. Hum Immunol 2009; 70( suppl 1): S58.
  • 25
    Mendler M, Kwok H, Franco E, Baron P, Weissman J, Ojogho O. Monitoring peripheral blood CD4+ adenosine triphosphate activity in a liver transplant cohort: insight into the interplay between hepatitis C virus infection and cellular immunity. Liver Transpl 2008; 14: 1313-1322.
  • 26
    Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al.; for QUADAS-2 Group. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011; 155: 529-536.
  • 27
    Zamora J, Abraira V, Muriel A, Khan K, Coomarasamy A. Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol 2006; 6: 31.
  • 28
    Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560.
  • 29
    Bhorade SM, Janata K, Vigneswaran WT, Alex CG, Garrity ER. Cylex ImmuKnow assay levels are lower in lung transplant recipients with infection. J Heart Lung Transplant 2008; 27: 990-994.
  • 30
    Sánchez-Velasco P, Rodrigo E, Valero R, Ruiz JC, Fernández-Fresnedo G, López-Hoyos M, et al. Intracellular ATP concentrations of CD4 cells in kidney transplant patients with and without infection. Clin Transplant 2008; 22: 55-60.
  • 31
    Kobashigawa JA, Kiyosaki KK, Patel JK, Kittleson MM, Kubak BM, Davis SN, et al. Benefit of immune monitoring in heart transplant patients using ATP production in activated lymphocytes. J Heart Lung Transplant 2010; 29: 504-508.
  • 32
    Husain S, Raza K, Pilewski JM, Zaldonis D, Crespo M, Toyoda Y, et al. Experience with immune monitoring in lung transplant recipients: correlation of low immune function with infection. Transplantation 2009; 87: 1852-1857.
  • 33
    Heikal NM, Hill HR, Barakat M, Martins T, Delgado JC, Stehlik J, et al. Laboratory monitoring of cell-mediated immunity and cytokines in cardiac transplant recipients for prediction of infection episodes [abstract]. J Heart Lung Transplant 2011; 30( suppl 4): S140.
  • 34
    Ling X, Xiong J, Liang W, Schroder PM, Wu L, Ju W, et al. Can immune cell function assay identify patients at risk of infection or rejection? A meta-analysis. Transplantation 2012; 93: 737-743.
  • 35
    Uemura T, Riley TR, Khan A, Hollenbeak C, Schreibman I, Ghahramani N, et al. Immune functional assay for immunosuppressive management in post-transplant malignancy. Clin Transplant 2011; 25: E32-E37.
  • 36
    Kegley K, Panjala C, Stein LL, Bruno CJ, Sellers M, Johnson MW, el al. In HCV-LT recipients ImmuKnow [TM] is a better cell mediated immunity monitoring method than conventional immunosuppressant drug trough level to prevent early graft fibrosis [abstract]. Hepatology 2011; 54( suppl 1): 627A-628A.
  • 37
    Alkhouri N, Hanouneh IA, Lopez R, Zein NN. Monitoring peripheral blood CD4+ adenosine triphosphate activity in recurrent hepatitis C and its correlation to fibrosis progression. Liver Transpl 2010; 16: 155-162.
  • 38
    Ravaioli M, Morelli C, Del Gaudio M, Zanello M, Berardi S, Ercolani G, et al. Immunosuppression monitoring by Cylex ImmuKnow test after liver transplantation: preliminary results of randomized prospective trial [abstract]. Transpl Int 2011; 24( suppl 2): 227.